Figure 2
Effect of IVIg on the in vivo OVA-specific T-cell proliferation. A total of 5 × 106 CFSE-stained spleen cells from DO11.10 transgenic mice were transferred to naive BALB/c mice. Mice (n = 4) were treated or not with IVIg before stimulation with OVA-ICs. OVA-specific T-cell expansion in the spleen of recipient BALB/c mice was determined 3 days later (A) by measuring the CFSE fluorescence intensity of splenic CD4+ cells by flow cytometry and (B) by evaluating of the number of OVA-specific T cells using the KJ1-26 mAb specific for the TCR expressed by DO11.10 mice. Results are representative of 3 independent experiments. *P < .001.
